Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
TNF inhibitors
10 evidence topics · 8 sources
Biologics guideline: recommendations for etanercept, infliximab, and adalimumab
Adalimumab: FDA-approved indication, dosage, and boxed warning
Adalimumab: Study Ps-I efficacy at week 16 and maintenance through week 52
| Endpoint at Week 16, n (%) | HUMIRA 40 mg every other week (N = 814) | Placebo (N = 398) |
|---|---|---|
| PGA clear or minimal | “506 (62%)” | “17 (4%)” |
| PASI 75 | “578 (71%)” | “26 (7%)” |
Etanercept: FDA-approved indication, dosage, boxed warning, and Study II efficacy at 3 months
“Starting Dose: 50 mg twice weekly for 3 months” (opens the source at this quote in a new tab)
“Maintenance Dose: 50 mg once weekly” (opens the source at this quote in a new tab)
| Outcome at 3 months, Study II, n (%) | Placebo (N = 204) | Etanercept 25 mg BIW (N = 204) | Etanercept 50 mg BIW (N = 203) |
|---|---|---|---|
| PASI 75 | “6 (3%)” | “66 (32%)” | “94 (46%)” |
| sPGA clear or minimal | “7 (3%)” | “75 (37%)” | “109 (54%)” |
Infliximab: FDA-approved indication, intravenous dosage, boxed warning, and week 10 PASI 75
| PASI 75 at Week 10, n (%) | Placebo | REMICADE 3 mg/kg | REMICADE 5 mg/kg |
|---|---|---|---|
| Psoriasis Study II (EXPRESS II) | “4 (2%)” | “220 (70%)” | “237 (75%)” |
| Psoriasis Study III (SPIRIT) | “3 (6%)” | “71 (72%)” | “87 (88%)” |
Certolizumab pegol: FDA-approved indication, dosage, and boxed warning
Decision aid: TNF inhibitors
| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
|---|---|---|
| Adalimumab | “31%” | “74–76% chance” |
| Certolizumab pegol | “24%” | “Not known at present” |
| Etanercept | “18%” | “67–73% chance” |
| Infliximab | “91%” | “54–74% chance” |
Network meta-analysis: infliximab and other TNF inhibitors
“At drug‐level, using SUCRA, infliximab had a better chance of reaching PASI 90 (versus placebo: RR 49.99, 95% CI 20.83 to 119.95; SUCRA = 91.8; moderate‐certainty evidence)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was also evidence of a higher risk of SAEs for participants on infliximab compared to methotrexate (RR 2.41, 95% CI 1.04 to 5.59).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Guselkumab, risankizumab, ixekizumab and bimekizumab were more effective than adalimumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ustekinumab, secukinumab, infliximab, ixekizumab, and tildrakizumab were more effective than etanercept.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
|---|---|---|---|
| Infliximab, 5 mg/kg | “80.4 (76.5-84.0)”View highlighted excerpt for this quote | “57.4 (52.2-62.8)”View highlighted excerpt for this quote | “26.5 (22.3-31.4)”View highlighted excerpt for this quote |
| Certolizumab pegol, 400 mg | “71.1 (65.4-76.5)”View highlighted excerpt for this quote | “45.6 (39.3-52.2)”View highlighted excerpt for this quote | “17.7 (13.8-22.3)”View highlighted excerpt for this quote |
| Adalimumab, 40 mg | “69.5 (66.0-72.6)”View highlighted excerpt for this quote | “43.7 (40.0-47.4)”View highlighted excerpt for this quote | “16.5 (14.2-19.0)”View highlighted excerpt for this quote |
| Etanercept, 25 mg twice weekly/50 mg once weekly | “40.1 (35.4-45.1)”View highlighted excerpt for this quote | “17.9 (14.9-21.4)”View highlighted excerpt for this quote | “4.2 (3.1-5.4)”View highlighted excerpt for this quote |